Ascentage Pharma: Interview With Co-Founder & CEO Dr. Dajun Yang About The Global Hematology-Oncology Company
By Amit Chowdhry ● Today at 8:00 AM
Ascentage Pharma is a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. With two approved products in China, Olverembatinib for chronic myeloid leukemia (CML) and Lisaftoclax for chronic lymphocytic leukemia (CLL), and a growing portfolio of global clinical trials, including registrational studies cleared by the FDA and the European Medicines Agency, Ascentage Pharma is advancing treatments across hematologic malignancies including CML, CLL, acute lymphoblastic leukemia (ALL), high- and intermediate-risk myelodysplastic syndrome (MDS), and is also expanding its pipeline in solid tumors. Pulse 2.0 interviewed Co-Founder, Chairman, and Chief Executive Officer Dr. Dajun Yang to learn more about the company.